Cyclophosphamide (Endoxan) is an alkylating agent synthesized by BROCK
et al. in 1958. During 2 years from June 1938 to July 1940, 287 cases of malignant neoplasmas were treated in our clinic. Among them 195 cases (55. 4%) received one or more kinds of antitumor substance, including cyclophosphamide in 34 cases(21. 4%), which consisted of 12 of stomach cancer, 5 of breast cancer, 4 of reticulum cell sarcoma, 3 of rectum cancer and each 1 of esophageal cancer, pancreatic cancer, thyroid cancer, lymphoepithelioma, ieiomyosarcoma, stomach myosarcoma and seminoma.
It was only in 4 cases (11. 7%) that the obvious clinical effects, subjectively and objectively, were checked. These cases were all with reticulum cell carcinoma.
Case 1, A. N. male, 35 years of age. Profuse reticulum cell sarcoma in the retroperitoneal cavity, operatively and pathologically attested. Later the tumor was revealed in the supraclavicular lymphnodes too. Daily 300 mg of cyclophosphamide were given intravenously during 34 days long. Tumor was distinguished, general condition was remarkably improved and left the hospital. The patient died of recurrence of the same neoplasma 5 months after the treatment.
Case 2, A. A. female, 28 years of age. Reticulum cell sarcoma of left neck, abdomen and right inguinum. Daily 200 mg of cyclophosphamide. Tumor distinguished.
Case 3, T. U. male, 48 years of age. Reticu lum cell sarcoma of abdomen and both inguinum. Recurrence after
60Co therapy. Daily 200 mg of cyclophosphamide during 34 days. Good response.
Case 4, T. W. male, 31 years of age. Reticulum cell sarcoma in the left n eck and inguinum. Daily 200 mg of intravenous cyclophosphamide. Good response. Side effects were also mentioned.
View full abstract